File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A)

TitleUse of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A)
Authors
Issue Date2010
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://jco.ascopubs.org
Citation
The 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2010. In Journal of Clinical Oncology, 2010, v. 28 suppl., abstarct no. e21009 How to Cite?
AbstractBackground: Biomarkers that predict benefit and define mechanisms of resistance to VEGF inhibitors are urgently needed. Methods: Plasma samples from patients (pts) treated on a phase II trial of XELOX-A in mCRC were analyzed via a multiplex ELISA platform (SearchLight; Aushon Biosystems, Inc.) for 44 factors related to tumor growth, angiogenesis, and inflammation. This platform was extensively optimized for use in cancer patients and nearly all factors had coefficients of variation between 10-20%. Patterns of expression were analyzed at baseline and on-treatment (day 28). Baseline and percent change from baseline (PCFB) values were correlated with progression free survival (PFS) using univariate Cox proportional hazard regression models and multivariate Cox models with leave-one-out cross validation. Results: 38 pts were evaluable at both baseline and on-treatment. Spearman's rank correlation coefficients were calculated for all pairs of analytes at both baseline and PCFB. Unsupervised hierarchical clustering of analytes was also performed to produce dendrogram plots. Data indicate that several analyte clusters reflect known biological categories. Predictors of PFS found to be significant using univariate models included: baseline analytes - von Willebrand Factor (p=0.001), angiopoietin-2 (p=0.034), VEGF-C (p=0.075); and PCFB analytes - TGFb2 (p=0.011), osteopontin (p=0.013), TGFb1 (p=0.0149), and IGF-1 (p=0.05). Leave-one-out cross validation analysis was performed to identify potential baseline and PCFB signatures for PFS. Kaplan-Meier plots and log-rank tests were also used to assess how well the set of analytes predicted the outcome of interest. Conclusions: Multiplex angiome analysis defines biologically and clinically informative patterns of expression. The current analysis has identified a profile that may predict for clinical benefit for mCRC patients treated with the VEGF inhibitor, bevacizumab. Confirmatory studies from separate datasets are now in progress.
DescriptionThis abstract will not be presented at the 2010 ASCO Annual Meeting but has been published in conjunction with the meeting - http://meetinglibrary.asco.org/content/47845-74
Persistent Identifierhttp://hdl.handle.net/10722/195785
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorNixon, Aen_US
dc.contributor.authorStarr, Men_US
dc.contributor.authorPang, HMHen_US
dc.contributor.authorBulusu, Aen_US
dc.contributor.authorHoneycutt, Wen_US
dc.contributor.authorAmara, Aen_US
dc.contributor.authorBendell, JCen_US
dc.contributor.authorHurwitz, Hen_US
dc.date.accessioned2014-03-10T04:53:28Z-
dc.date.available2014-03-10T04:53:28Z-
dc.date.issued2010en_US
dc.identifier.citationThe 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2010. In Journal of Clinical Oncology, 2010, v. 28 suppl., abstarct no. e21009en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/195785-
dc.descriptionThis abstract will not be presented at the 2010 ASCO Annual Meeting but has been published in conjunction with the meeting - http://meetinglibrary.asco.org/content/47845-74-
dc.description.abstractBackground: Biomarkers that predict benefit and define mechanisms of resistance to VEGF inhibitors are urgently needed. Methods: Plasma samples from patients (pts) treated on a phase II trial of XELOX-A in mCRC were analyzed via a multiplex ELISA platform (SearchLight; Aushon Biosystems, Inc.) for 44 factors related to tumor growth, angiogenesis, and inflammation. This platform was extensively optimized for use in cancer patients and nearly all factors had coefficients of variation between 10-20%. Patterns of expression were analyzed at baseline and on-treatment (day 28). Baseline and percent change from baseline (PCFB) values were correlated with progression free survival (PFS) using univariate Cox proportional hazard regression models and multivariate Cox models with leave-one-out cross validation. Results: 38 pts were evaluable at both baseline and on-treatment. Spearman's rank correlation coefficients were calculated for all pairs of analytes at both baseline and PCFB. Unsupervised hierarchical clustering of analytes was also performed to produce dendrogram plots. Data indicate that several analyte clusters reflect known biological categories. Predictors of PFS found to be significant using univariate models included: baseline analytes - von Willebrand Factor (p=0.001), angiopoietin-2 (p=0.034), VEGF-C (p=0.075); and PCFB analytes - TGFb2 (p=0.011), osteopontin (p=0.013), TGFb1 (p=0.0149), and IGF-1 (p=0.05). Leave-one-out cross validation analysis was performed to identify potential baseline and PCFB signatures for PFS. Kaplan-Meier plots and log-rank tests were also used to assess how well the set of analytes predicted the outcome of interest. Conclusions: Multiplex angiome analysis defines biologically and clinically informative patterns of expression. The current analysis has identified a profile that may predict for clinical benefit for mCRC patients treated with the VEGF inhibitor, bevacizumab. Confirmatory studies from separate datasets are now in progress.-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://jco.ascopubs.org-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.titleUse of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A)en_US
dc.typeConference_Paperen_US
dc.identifier.emailPang, HMH: herbpang@hku.hken_US
dc.identifier.authorityPang, HMH=rp01857en_US
dc.identifier.volume28en_US
dc.identifier.issuesuppl.-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats